Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 10, 2004, Pages 1121-1127

  Fujiwara, Keishi ^a   Higashi, Toshihiro ^b   Nouso, Kazuhiro ^a   Nakatsukasa, Harushige ^a   Kobayashi, Yoshiyuki ^a   Uemura, Masayuki ^a   Nakamura, Shin Ichiro ^a   Sato, Shuichiro ^a   Hanafusa, Tadashi ^c   Yumoto, Yasuhiro ^c   Naito, Ichiro ^d   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Okayama Citizens Hospital   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d Shigei Medical Research Institute   (Japan)

Author keywords

Immune tolerance; Liver; Neoplasm; Tumor escape

Indexed keywords

B7 ANTIGEN; BETA 2 MICROGLOBULIN; CD86 ANTIGEN; HEAT SHOCK PROTEIN 70; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

AGED; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER GRADING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; LIVER; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR DIFFERENTIATION;

EID: 5644299276     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03467.x     Document Type: Article

References (39)

1. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992; 15: 948-63.
2. Miyagawa S, Kawasaki S, Makuuchi M. Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology 1996; 24: 307-10.
3. Jager E, Jager D, Knuth A. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev. 1999; 18: 143-50.
4. Mackensen A, Herbst B, Chen JL. et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34 (+) hematopoietic progenitor cells. Int. J. Cancer 2000; 86: 385-92.
5. Jager E, Jager D, Knuth A. Strategies for the development of vaccines to treat breast cancer. Recent Results Cancer Res. 1998; 152: 94-102.
6. Kariyama K, Higashi T, Kobayashi Y et al. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma. Br. J. Cancer 1999; 81: 1080-7.
7. Kobayashi Y, Higashi T, Nouso K et al. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J. Hepatol. 2000; 32: 612-17.
8. Bodmer WF, Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann. NY Acad. Sci. 1993; 690: 42-9.
9. Kefford RF, Calabi F, Fearnley IM, Burrone OR, Milstein C. Serum beta 2-microglobulin binds to a T-cell differentiation antigen and increases its expression. Nature 1984; 308: 641-2.
10. Shields MJ, Kubota R, Hodgson W, Jacobson S, Biddison WE, Ribaudo RK. The effect of human beta2-microglobulin on major histocompatibility complex I peptide loading and the engineering of a high affinity variant. Implications for peptide-based vaccines. J. Biol. Chem. 1998; 273: 28010-18.
11. Young D, Roman E, Moreno C, O'Brien R, Born W. Molecular chaperones and the immune response. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1993; 339: 363-7; discussion 367-8.
12. Caux C, Vanbervliet B, Massacrier C et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 1994; 180: 1841-7.
13. Lanier LL, O'Fallon S, Somoza C et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 1995; 154: 97-105.
14. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int. J. Cancer 1990; 46: 1029-34.
15. Vogel J, Tanaka K, Hoekzema GS, Jay G. Experimental strategies for modification of histocompatibility antigens in tumor cells. Cancer Metastasis Rev. 1987; 6: 677-83.
16. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J. Interferon Cytokine Res. 1999; 19: 697-703.
17. Stearns ME, Wang M. Antimestatic and antitumor activities of interleukin 10 in transfected human prostate PC-3 ML clones: orthotopic growth in severe combined immunodeficient mice. Clin. Cancer Res. 1998; 4: 2257-63.
18. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J. Natl Cancer Inst. 1996; 88: 536-41.
19. Li J, Yang Y, Inoue H, Mori M, Akiyoshi T. The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon gamma and interleukin-10. Cancer Immunol. Immunother. 1996; 43: 213-19.
20. Matsuda M, Salazar F, Petersson M et al. Interleukin 10 pretreatment protects target cells from tumor- and allospecific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med. 1994; 180: 2371-6.
21. Salazar-Onfray F, Charo J, Petersson M et al. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J. Immunol. 1997; 159: 3195-202.
22. Paterson AC, Sciot R, Kew MC, Callea F, Dusheiko GM, Desmet VJ. HLA expression in human hepatocellular carcinoma. Br. J. Cancer 1988; 57: 369-73.
23. Kurokohchi K, Carrington M, Mann DL et al. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 1996; 23: 1181-8.
24. Tatsumi T, Takehara T, Katayama K et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology 1997; 25: 1108-14.
25. Wadee AA, Paterson A, Coplan KA, Reddy SG. HLA expression in hepatocellular carcinoma cell lines. Clin. Exp. Immunol. 1994; 97: 328-33.
26. Angus R, Collins CM, Symes MO. Expression of major histocompatibility complex (MHC) antigens and their loss on culture in renal carcinoma. Eur. J. Cancer 1993; 15: 2158-60.
27. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-93.
28. Vyberg M, Nielsen S. Dextran polymer conjugate two-step visualization system for immunohistochemistry. Appl. Immunohistochem. 1998; 6: 3-10.
29. Fukusato T, Gerber MA, Thung SN, Ferrone S, Schaffner F. Expression of HLA class I antigens on hepatocytes in liver disease. Am. J. Pathol. 1986; 123: 264-70.
30. Chen L. Manipulation of T cell response to tumors by targeting on costimulatory pathway. Leukemia 1997; 11 (Suppl. 3): 567-9.
31. Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 1994; 153: 421-8.
32. Moro M, Gasparri AM, Pagano S et al. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules. Cancer Res. 1999; 59: 2650-6.
33. Tarte K, Zhang XG, Legouffe E et al. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J. Immunol. 1999; 163: 514-24.
34. McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc. Natl Acad. Sci. USA 1995; 92: 8059-63.
35. Thomas GR, Chen Z, Oechsli MN, Hendler FJ, Van Waes C. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int. J. Cancer 1999; 82: 377-84.
36. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998; 27: 407-14.
37. Kim J, Modlin RL, Moy RL et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J. Immunol. 1995; 155: 2240-7.
38. Wang Q, Redovan C, Tubbs R et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int. J. Cancer 1995; 61: 780-5.
39. Kakumu S, Okumura A, Ishikawa T et al. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin. Exp. Immunol. 1997; 109: 458-63.